What the FDA labels say about taking them together
Dexrazoxane and doxorubicin
Dexrazoxane's FDA label of June 23, 2025 names doxorubicin in its warnings and precautions section, and doxorubicin's label names dexrazoxane too. The doxorubicin label: “Consider the use of dexrazoxane to reduce the incidence and severity of cardiomyopathy due to doxorubicin hydrochloride administration in patients who have received a cumulative doxorubicin hydrochloride dose of 300 …”
Check it at the source: the dexrazoxane FDA label on DailyMed (effective June 23, 2025, Gland Pharma Limited); the doxorubicin FDA label on DailyMed (effective May 5, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the dexrazoxane label say about doxorubicin?
Dexrazoxane label, warnings and precautionsIn a trial conducted in patients with metastatic breast cancer who were treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC) with or without dexrazoxane for injection starting with their first cycle of FAC therapy, patients who were randomized to receive dexrazoxane for injection had a lower response rate (48% vs. 63%) and shorter time to progression than patients who were randomized to receive placebo.
Source: FDA drug label (Dexrazoxane), Gland Pharma Limited, effective June 23, 2025 (SPL set c9c625fc-8852-4ed4-bcf2-63f46a706782), via openFDA; the full label on DailyMed
What does the doxorubicin label say about dexrazoxane?
Doxorubicin label, drug interactionsIn a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin hydrochloride-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p = 0.007) and shorter time to progression compared to doxorubicin hydrochloride-based chemotherapy alone.
Doxorubicin label, warnings and precautionsConsider the use of dexrazoxane to reduce the incidence and severity of cardiomyopathy due to doxorubicin hydrochloride administration in patients who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m 2 and who will continue to receive doxorubicin hydrochloride.
Source: FDA drug label (Doxorubicin Hydrochloride), Pfizer Laboratories Div Pfizer Inc, effective May 5, 2026 (SPL set 1fd148fb-0fbc-4b6f-b790-23546fb46a71), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexrazoxane | Doxorubicin | |
|---|---|---|
| Labeled for | n/a | Leukemia, lymphoma and myeloma, Breast cancer |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once